Literature DB >> 8548553

Genetic instability of a MoMLV-based antisense double-copy retroviral vector designed for HIV-1 gene therapy.

U Junker1, E Böhnlein, G Veres.   

Abstract

We constructed a retroviral vector encoding a mutant tRNA(imet) gene followed by a HIV-1 rev-specific antisense sequence in the U3 region of the 3' long terminal repeat (LTR). This Moloney murine leukemia virus (MoMLV)-based double-copy retroviral vector was used to transduce human lymphoblastoid T-cell lines (CEM, Jurkat). In some clonal cell lines the expected short transcript initiated either from the 5' or 3' LTR tRNA-alpha rev gene was not detectable by Northern blot analyses of transduced, G418-resistant cells with an alpha rev-specific oligonucleotide probe. In other clonal cells, neither the short polymerase III transcript nor the full-length genomic polymerase II transcript (containing the 3' LTR tRNA-alpha rev gene) was detectable when compared with the transduced cell pool. Southern blot and DNA-polymerase chain reaction (PCR) analyses specific for the tRNA-alpha rev cassette in the 5' or 3' LTR of the retroviral vector suggested that the transfer of the 3' LTR U3 region to the 5' LTR was incorrect in most proviruses. These data were confirmed by DNA sequence analyses of several clonal lines demonstrating deletions and insertions. In summary, our results indicate that this retroviral vector design with direct repeats flanking the polymerase III transcription unit plus the alpha rev insert is prone to genetic rearrangements and consequently not useful for the development of gene therapy protocols.

Entities:  

Mesh:

Substances:

Year:  1995        PMID: 8548553

Source DB:  PubMed          Journal:  Gene Ther        ISSN: 0969-7128            Impact factor:   5.250


  8 in total

1.  Mechanism of reduction in titers from lentivirus vectors carrying large inserts in the 3'LTR.

Authors:  Fabrizia Urbinati; Paritha Arumugam; Tomoyasu Higashimoto; Anil Perumbeti; Kyle Mitts; Ping Xia; Punam Malik
Journal:  Mol Ther       Date:  2009-04-21       Impact factor: 11.454

2.  Scaffold attachment region-mediated enhancement of retroviral vector expression in primary T cells.

Authors:  M Agarwal; T W Austin; F Morel; J Chen; E Böhnlein; I Plavec
Journal:  J Virol       Date:  1998-05       Impact factor: 5.103

3.  Multigene antiviral vectors inhibit diverse human immunodeficiency virus type 1 clades.

Authors:  A Gervaix; X Li; G Kraus; F Wong-Staal
Journal:  J Virol       Date:  1997-04       Impact factor: 5.103

4.  A uniquely stable replication-competent retrovirus vector achieves efficient gene delivery in vitro and in solid tumors.

Authors:  C R Logg; C K Tai; A Logg; W F Anderson; N Kasahara
Journal:  Hum Gene Ther       Date:  2001-05-20       Impact factor: 5.695

5.  Efficient downregulation of multiple mRNA targets with a single shRNA-expressing lentiviral vector.

Authors:  Stepan P Chumakov; Julia E Kravchenko; Vladimir S Prassolov; Elena I Frolova; Peter M Chumakov
Journal:  Plasmid       Date:  2010-01-11       Impact factor: 3.466

6.  The 3' region of the chicken hypersensitive site-4 insulator has properties similar to its core and is required for full insulator activity.

Authors:  Paritha I Arumugam; Fabrizia Urbinati; Chinavenmeni S Velu; Tomoyasu Higashimoto; H Leighton Grimes; Punam Malik
Journal:  PLoS One       Date:  2009-09-10       Impact factor: 3.240

7.  A versatile viral system for expression and depletion of proteins in mammalian cells.

Authors:  Eric Campeau; Victoria E Ruhl; Francis Rodier; Corey L Smith; Brittany L Rahmberg; Jill O Fuss; Judith Campisi; Paul Yaswen; Priscilla K Cooper; Paul D Kaufman
Journal:  PLoS One       Date:  2009-08-06       Impact factor: 3.240

8.  Kunjin replicon-based simian immunodeficiency virus gag vaccines.

Authors:  Itaru Anraku; Vladislav V Mokhonov; Paweena Rattanasena; Ekaterina I Mokhonova; Jason Leung; Gorben Pijlman; Andrea Cara; Wayne A Schroder; Alexander A Khromykh; Andreas Suhrbier
Journal:  Vaccine       Date:  2008-04-21       Impact factor: 3.641

  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.